Skip to content
10-K

Annual Report

NEXIEN BIOPHARMA, INC.

0001493152-23-034480

← back to feed
Filed
Sep 28, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Sep 25, 2023 64.77M sh
Operating Income FY 2023 · Jun 30, 2023 $11.3M
Shares Diluted FY 2023 · Jun 30, 2022 57.86M sh
Operating Cash Flow FY 2023 · Jun 30, 2022 −$75.14K
Cash And Equivalents FY 2023 · Jun 30, 2022 $116.9K
Current Liabilities FY 2023 · Jun 30, 2022 $242.12K
Total Liabilities FY 2023 · Jun 30, 2022 $242.12K
Current Assets FY 2023 · Jun 30, 2022 $124.52K
Total Assets FY 2023 · Jun 30, 2022 $124.52K
Eps Diluted FY 2023 · Jun 30, 2022 −$0.01
Eps Basic FY 2023 · Jun 30, 2022 −$0.01
Sga Expense FY 2023 · Jun 30, 2022 $530.76K
Rd Expense FY 2023 · Jun 30, 2022 $0
Net Income FY 2023 · Jun 30, 2022 −$626.36K
Stockholders Equity FY 2023 · Jun 30, 2021 −$13.78K